Education
About Us
Working with TipRanks
Follow Us
IDEAYA Biosciences (IDYA)
NASDAQ:IDYA
IDYA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$16.95 - $44.42
Previous CloseN/A
Volume96.34K
Average Volume (3M)948.13K
Market Cap
$1.61B
Enterprise Value$1.83B
Total Cash (Recent Filing)$84.38M
Total Debt (Recent Filing)$19.17M
Price to Earnings (P/E)―
Beta1.21
Next Earnings
May 13, 2025EPS Estimate
-0.68Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.30
Shares Outstanding87,537,390
10 Day Avg. Volume968,760
30 Day Avg. Volume948,128
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)229.97
Price to Cash Flow (P/CF)-3.30
P/FCF Ratio0.00
Enterprise Value/Market Cap1.14
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit261.32
Enterprise Value/Ebitda-5.63
Forecast
1Y Price Target
$53.17Price Target Upside189.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
IDEAYA Biosciences News
---
Bulls Say, Bears Say
Bulls Say
Clinical Pipeline ProgressDLL3 ADC IDE849 clinical update showed a 73% partial response rate in pre-treated SCLC patients, with no adverse events leading to discontinuation.
Financial StabilityIDYA reported cash and cash equivalents at $1.1 billion, which they expect will provide cash runway into 2028.
Strategic PartnershipsThe company announced an additional clinical study collaboration and supply agreement with GILD to evaluate the combination of IDE397 with Trodelvy in MTAP-del NSCLC, expanding their ongoing collaboration efforts.
Bears Say
Future Financial PlanningThe most significant change is the addition of $250mn equity raises in 2026, 2027 and 2028 due to an expected increase in cash outflow as the early pipeline advances.
Regulatory ChallengesThe company's management noted that the timing for a conference readout on mUM data will be challenging.
Strategic Collaboration ChangesIDYA & AMGN winding down their MTAP collaboration via mutual agreement; clearing event & unsurprising, given IDYA's new internal PRMT5 inhibitor, and mgmt messaging.
---
Ownership Overview
0.89% Insiders
34.49% Mutual Funds
28.74% Other Institutional Investors
22.47% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IDYA FAQ
What was IDEAYA Biosciences’s price range in the past 12 months?
IDEAYA Biosciences lowest stock price was $16.95 and its highest was $44.42 in the past 12 months.
What is IDEAYA Biosciences’s market cap?
IDEAYA Biosciences’s market cap is $1.61B.
When is IDEAYA Biosciences’s upcoming earnings report date?
IDEAYA Biosciences’s upcoming earnings report date is May 13, 2025 which is in 50 days.
How were IDEAYA Biosciences’s earnings last quarter?
IDEAYA Biosciences released its earnings results on Feb 13, 2025. The company reported -$1.49 earnings per share for the quarter, missing the consensus estimate of -$0.629 by -$0.861.
Is IDEAYA Biosciences overvalued?
According to Wall Street analysts IDEAYA Biosciences’s price is currently Undervalued.
Does IDEAYA Biosciences pay dividends?
IDEAYA Biosciences does not currently pay dividends.
What is IDEAYA Biosciences’s EPS estimate?
IDEAYA Biosciences’s EPS estimate is -0.68.
How many shares outstanding does IDEAYA Biosciences have?
IDEAYA Biosciences has 87,537,390 shares outstanding.
What happened to IDEAYA Biosciences’s price movement after its last earnings report?
IDEAYA Biosciences reported an EPS of -$1.49 in its last earnings report, missing expectations of -$0.629. Following the earnings report the stock price went down -5.421%.
Which hedge fund is a major shareholder of IDEAYA Biosciences?
Currently, no hedge funds are holding shares in IDYA
---
IDEAYA Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$53.17 (189.12% Upside)
$53.17 (189.12% Upside)
Blogger Sentiment
Bullish
IDYA Sentiment 66%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 185.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.5%
Last 30 Days ▼ 5.6%
Last 30 Days ▼ 5.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-59.69%
12-Months-Change
Fundamentals
Return on Equity
-32.67%
Trailing 12-Months
Asset Growth
73.12%
Trailing 12-Months
Company Description
IDEAYA Biosciences
IDEAYA Biosciences, Inc. develops cancer therapeutics. It is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company operates and manages its business as one operating and reportable segment, which is the business of research and development for oncology-focused precision medicine. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.
---
IDYA Stock 12 Month Forecast
Average Price Target
$53.17
▲(189.12% Upside)
Technical Analysis
Best Analysts Covering IDYA
1 Year
1 Year Success Rate
7/12 ratings generated profit
1 Year Average Return
+34.69%
reiterated a buy rating 5 months ago
Copying Matthew Biegler's trades and holding each position for 1 Year would result in 58.33% of your transactions generating a profit, with an average return of +34.69% per trade.
---